ADVERTISEMENT

Kudankulam: India seeks to allay Sri Lankan fears

May 07, 2014 01:50 am | Updated November 16, 2021 06:47 pm IST - NEW DELHI/COLOMBO:

The two countries discuss collaboration in nuclear medicine

Weeks after India signed the agreement for building units 3 and 4 of the Kudankulam Nuclear Power Plant, New Delhi, at a meeting in Colombo, sought to allay fears in Sri Lanka over the safety of the project.

The safety of the plant, among other issues, came up for discussion at the meeting on comprehensive civil nuclear cooperation between the two countries held in Colombo on Monday and Tuesday, it is reliably learnt.

According to government sources in New Delhi, the two countries discussed possible collaboration in the field of nuclear medicine. Sri Lanka reportedly also sought training in the field, covering certain specialisations.

ADVERTISEMENT

Indian High Commission officials in Colombo said Amandeep Singh Gill, Joint Secretary (Disarmament), Ministry of External Affairs, led the Indian delegation at the second round of talks, held as a follow-up to the initial round of discussions held in New Delhi in 2012.

While there has been an ongoing dialogue between the two countries on possible civil nuclear cooperation over the years, it was sidetracked by other issues dominating bilateral relations. All the same, following the Fukushima disaster, Sri Lanka raised concern at how safe the > Kudankulam nuclear plants in Tamil Nadu are.

Government sources ruled out any possibility of India selling nuclear reactors to its neighbour. There was no specific request from the Sri Lankan side either, it is learnt.

ADVERTISEMENT

They also said an agreement did not look likely in the near future.

This is a Premium article available exclusively to our subscribers. To read 250+ such premium articles every month
You have exhausted your free article limit.
Please support quality journalism.
You have exhausted your free article limit.
Please support quality journalism.
The Hindu operates by its editorial values to provide you quality journalism.
This is your last free article.

ADVERTISEMENT

ADVERTISEMENT